FDA — authorised 30 March 2022
- Application: ANDA209997
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: SODIUM PHOSPHATES
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
🇺🇸 Acid Reflux Relief in United States
FDA authorised Acid Reflux Relief on 30 March 2022
Marketing authorisations
FDA — authorised 21 June 2024
- Application: ANDA218314
- Marketing authorisation holder: AM REGENT
- Local brand name: SODIUM PHOSPHATES
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 23 February 2026
- Application: ANDA220683
- Marketing authorisation holder: CAPLIN
- Local brand name: SODIUM PHOSPHATES
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA
- Status: approved
Acid Reflux Relief in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Acid Reflux Relief approved in United States?
Yes. FDA authorised it on 30 March 2022; FDA authorised it on 21 June 2024; FDA authorised it on 23 February 2026.
Who is the marketing authorisation holder for Acid Reflux Relief in United States?
FRESENIUS KABI USA holds the US marketing authorisation.